HENDERSON, Nev. — (BUSINESS WIRE) — November 16, 2015 — Rainbow Coral Corp. (OTCQB: RBCC) and partner Nano3D Biosciences (n3D) are pondering potential future moves as researchers make tremendous strides in the field of bioprinting, meaning it may soon be possible to use additive manufacturing technology to engineer an entire human body.
Researchers have already printed several human organs and tissues, including hair, noses, ears, bones and spinal parts. Thanks to these remarkable advances, people suffering from deformities or injuries can have their disfigured or missing tissues restored, giving them an enhanced quality of life.
“What was once only possible in science fiction is moving ever closer to commercial reality,” said RBCC CEO Kimberly Palmer. “Bioprinting can change the world for the better in terms of eradicating or mitigating the effect of disease through personalized drugs, in tissue restoration and repair, and even cosmetic surgery. RBCC and n3D intend to be on the forefront of this life-altering technology and we will continue to pursue research projects, joint ventures and partnerships to make bioprinting commercially available.”
Bioprinting, while still in its infancy, is expected to become a booming segment when it reaches maturity. According to some reports, bioprinting could become a $7 billion industry, which would mean bioprinting would make up half of the overall 3D printing market.
n3D’s innovative Bioassembler and Magnetic 3D devices use biocompatible magnetic nanoparticles to magnetically bioprint and levitate human cells, allowing them to grow into 3D structures much faster and more simply than competing technologies. The company has recently signed global distribution agreements to make its bioprinting products available to a wide array of government institutions and private researchers worldwide.
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. ( RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President and CEO